ACTG announcement
CHAPEL HILL, N.C., April 24, 2026 — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5402, an important new study that researchers hope will expand understanding of how to best treat depressive disorders and mild neurocognitive disorder (MND) among people living with HIV. A5402 is a phase 2, randomized, open-label clinical trial evaluating the safety and efficacy of pramipexole (a drug that stimulates receptors for the neurotransmitter dopamine in the brain) compared to escitalopram (a traditional antidepressant that modulates serotonin, a different neurotransmitter) to treat depressive disorders with or without MND among people living with HIV.
Depressive disorders and MND both affect a significant portion of people living with HIV in the United States and worldwide, even when their HIV is successfully managed and treated with antiretroviral therapy. People with MND have worse cognitive performance around memory, language, and multitasking than people who do not have MND. Combined, depressive disorders and MND can affect up to 80 percent of people living with HIV, a two- to four-fold increase compared to people who do not have HIV.
Read the full announcement here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.